New legal threat follows $650mn settlement with US government over company’s opioid work
Firm settles criminal investigation and former senior partner admits obstruction of justice
The evidence points to changes in the drug supply
Payment would significantly raise cost to firm of its past work for opioid makers
Analysis points to potential of drugs such as Ozempic beyond tackling obesity and diabetes
New paper by former Big Law associate flags concerns over role in episodes such as the opioid crisis
Move is the first time in six years that Beijing will restrict the ingredients used in the drug
New compound increases strength of antidote for fentanyl and other lethal drugs
Plus, troubles are brewing among loans favoured by private equity, and venture capital makes a big bet on defence tech
Members of OxyContin maker’s founding family had fought to uphold protections in $6bn opioid settlement
US state to buy naloxone nasal spray from generics maker and distribute medication under its own brand
With revenues having more than doubled since 2019, to $10bn, US pharma group targets painkillers
Grand jury set up to hear evidence on consulting for drugmakers tied to addiction epidemic
Agreement with French group is the first prosecutors have made with an advertising agency over its alleged role
Beijing meeting aims to advance agreements between Joe Biden and Xi Jinping during summit last year
Members of the company’s founding family fight to uphold protections from $6bn opioid bankruptcy settlement in closely watched case
Plan to curb supply of opioid’s precursor chemicals comes ahead of summit between Joe Biden and Xi Jinping
The illicit trade routes responsible for the worst overdose crisis in US history
Hedge funds seize control of Mallinckrodt in latest case exposing flaws of US mass tort playbook
Treasury’s move comes as Washington tries to combat flow of deadly opioid
Consultancy admits no wrongdoing as it resolves claims from municipalities and school districts
Experimentation continues on measures to tackle addiction and fatal overdoses
Drug producer’s prospects are poor enough that its reset enterprise value is just $3bn
The new six-part Netflix series is a comprehensive and pacy examination of mass greed and its consequences
Justices will consider whether the law permits the waiver of future claims against parties not in bankruptcy
